Loading...
•
Mar 31, 2024
Amgen Q1 2024 Earnings Report
Amgen's financial performance for Q1 2024 showed revenue growth driven by strong volume growth and contributions from the Horizon Therapeutics acquisition, but earnings were impacted by increased operating expenses.
Key Takeaways
Amgen reported a 22% increase in total revenues to $7.4 billion for the first quarter of 2024, driven by a 25% increase in volume and the acquisition of Horizon Therapeutics. GAAP loss per share was $0.21, while non-GAAP EPS decreased 1% to $3.96. The company generated $0.5 billion in free cash flow.
Total revenues increased by 22% to $7.4 billion, with product sales growing by 22% due to a 25% increase in volume.
U.S. volume grew by 29%, and ex-U.S. volume grew by 17%.
Horizon Therapeutics acquisition contributed $914 million in sales, with key products like TEPEZZA, KRYSTEXXA and UPLIZNA.
GAAP loss per share was $0.21, while non-GAAP EPS decreased 1% to $3.96, impacted by higher operating and interest expenses.
Amgen
Amgen
Amgen Revenue by Segment
Amgen Revenue by Geographic Location
Revenue by Segment
Repatha Revenue
CapyFin.comEVENITY Revenue
CapyFin.comProlia Revenue
CapyFin.comOtezla Revenue
CapyFin.comEnbrel Revenue
CapyFin.comKyprolis Revenue
CapyFin.comXGEVA Revenue
CapyFin.comVectibix Revenue
CapyFin.comNplate Revenue
CapyFin.comBLINCYTO Revenue
CapyFin.comAranesp Revenue
CapyFin.comParsabiv Revenue
CapyFin.comAMJEVITA / AMGEVITA Revenue
CapyFin.comMVASI Revenue
CapyFin.comNeulasta Revenue
CapyFin.comUPLIZNA Revenue
CapyFin.comTEZSPIRE Revenue
CapyFin.comOther products Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
For the full year 2024, Amgen expects total revenues in the range of $32.5 billion to $33.8 billion and non-GAAP EPS in the range of $19.00 to $20.20.
Positive Outlook
- Total revenues are expected to be in the range of $32.5 billion to $33.8 billion.
- Capital expenditures are anticipated to be approximately $1.1 billion.
- On a GAAP basis, EPS is projected to be in the range of $7.15 to $8.40.
- On a GAAP basis, the tax rate is expected to be in the range of 9.5% to 11.0%.
- On a non-GAAP basis, the tax rate is expected to be in the range of 15.0% to 16.0%.
Challenges Ahead
- Share repurchases are not expected to exceed $500 million.
- GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation
- GAAP diluted EPS guidance does not include changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments.
- Global economic conditions may magnify certain risks that affect our business.
- Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.
Revenue & Expenses
Visualization of income flow from segment revenue to net income